EUVIMEDEUVIMED entdecken
Crossref

Tumor downstaging with particles chemoembolization (DEB-TACE) vs. conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma: a retrospective study

Χλωρογιάννης, Δημήτριος Δαυίδ Ι.

Aristotle University of Thessaloniki · 01.01.2025

DOI: 10.26262/heal.auth.ir.367990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2025. Verfasst von Χλωρογιάννης und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) constitutes a major cause of mortality and morbidity worldwide with limited treatment options available. Surgery and liver transplantation remain the gold-standard curative intent treatments, but not every patient is a surgical candidate due to disease extent, comorbidities and advanced liver disease at diagnosis. As such, transarterial chemoembolization (TACE) with particles (drug eluting beads; DEB-TACE) or without (conventional-TACE; cTACE) have been proposed as bridging therapy for downstaging to surgery or transplantation. However, data directly comparing DEB-TACE and cTACE are lacking.

Aim

To retrospectively compare the conversion rates for downstaging and oncologic outcomes of DEB-TACE vs cTACE in patients with advanced liver disease and unresectable HCC. Materials and Methods: Institutional database research identified all HCC patients who underwent TACE (DEB-TACE or cTACE) from 2019 to 2024. Primary outcome was conversion rate and secondary outcomes were overall survival (OS), local- and progression-free survival (LTPFS and PFS). Differences were assessed with the Fisher and Wilcoxon rank-sum test. Survival metrics were estimated using the Kaplan-Meier method and compared using Log-Rank testing.

Results

The final cohort included 27 patients who underwent cTACE (n=21) or DEB-TACE (n=6). No significant difference was found in the conversion rates of the DEB-TACE and cTACE group (17% vs 33%, p-value=0.63) and the overall response rates (83% and 71%, p-value > 0.99). The overall adverse events were minimal (n=2) with no difference between the two groups. After comparing cTACE vs DEB-TACE, the estimated 14-month OS rates were 75% and 63%, the LTPFS rates were 88% and 80% and the PFS rates were 100% and 53%, respectively. No difference was observed for any survival outcome.

Conclusion

This thesis suggests that cTACE and DEB-TACE, are equally safe and can be considered to downstage HCC to resectable stage and/or prolong survival until liver transplantation in patients with advanced liver disease.

Schlagwörter

hepatocellular carcinomatransarterial chemoembolizationdrug-eluting beadsDEB-TACEtumor downstagingbridging therapyunresectable liver canceradvanced liver diseaseliver transplantationconversion to surgery

Zitieren

APA

Χλωρογιάννης, & Ι., Δ. Δ. (2025). Tumor downstaging with particles chemoembolization (DEB-TACE) vs. conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma: a retrospective study. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.367990

Vancouver

Χλωρογιάννης, Ι. ΔΔ. Tumor downstaging with particles chemoembolization (DEB-TACE) vs. conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma: a retrospective study. Aristotle University of Thessaloniki. 2025. doi:10.26262/heal.auth.ir.367990

BibTeX
@article{2025,
  author = {Χλωρογιάννης and Ι., Δημήτριος Δαυίδ},
  title = {Tumor downstaging with particles chemoembolization (DEB-TACE) vs. conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma: a retrospective study},
  journal = {Aristotle University of Thessaloniki},
  year = {2025},
  doi = {10.26262/heal.auth.ir.367990}
}
Kostenlos starten →